Clodronate Liposomes are currently the most mature, convenient, and cost-effective tool for macrophage depletion. They can effectively eliminate macrophages in various tissues and sites within animals, including the liver, spleen, lungs, and blood, and are currently the most widely used method for macrophage depletion. After Clodronate Liposomes are injected into a living organism, they are phagocytosed by macrophages. Under the action of lysosomal phosphatases within the macrophages, the clodronate dissolved in the liposomes is gradually released and accumulates intracellularly. When a certain concentration is reached, the macrophages will suffer irreversible damage, inducing apoptosis. This product is an upgraded combination pack based on the original Clodronate Liposomes (Cat#40337ES), containing both an In Vivo Macrophage Depletion Reagent and an Empty Liposome Control for enhanced experimental convenience. Features Efficient Macrophage Depletion: Efficient macrophage depletion through clodronate-encapsulated liposomes. High specificity: Selectively targeting phagocytic macrophages and monocytes. Validated in Multiple Models: Validated in multiple animal models for immunology, inflammation, and tumor microenvironment studies. Ready-to-Use Format: Ready-to-use formulation for convenient and reproducible experiments. Components Components No. Name Cat.No. Storage 40339ES05 40339ES08 40339ES10 40337ES Clodronate Liposomes 2 mL 5 mL 10 mL 2~8℃ 40338ES Control Liposomes(PBS) 2 mL 5 mL 10 mL 2~8℃ Figure 1. Case Study: Efficient Depletion of Perivascular Macrophages in the Mouse Brain Figure 1. Efficient depletion of perivascular macrophages in the brain following intracisternal administration of Yeasen Macrophage Depletion Reagent (Cat. No. 40339ES). Mice received a single injection of 4 µL clodronate liposomes (CLO) into the cisterna magna; control animals received an equal volume of PBS. Brain tissues were collected 7 days post-injection and sectioned for immunofluorescence staining using anti-CD163 antibody (Cell Signaling Technology, #24595) to label perivascular macrophages. Quantification of macrophages per unit vessel length showed a significant reduction in the CLO group (33.10 ± X.XX) compared to PBS controls (96.59 ± X.XX), corresponding to a ~66% decrease (or approximately 34% of control levels). Note: If CD26 was intended instead of CD163, please confirm—CD163 is a canonical marker for perivascular macrophages in the CNS; CD26 is atypical for this population. Learn More: Clodronate Liposomes for Macrophage Depletion: Precise Clodronate Content, Controlled Particle Size —Ensuring Safe and Reliable in vivo Experiments
